Impact of target volume coverage with Radiation Therapy Oncology Group (RTOG) 98-05 guidelines for transrectal ultrasound guided permanent Iodine-125 prostate implants

Eric M. Horwitz, Raj K. Mitra, Robert G. Uzzo, Indra J. Das, Wayne H. Pinover, Alexandra L. Hanlon, Shawn W. McNeeley, Gerald E. Hanks

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: Despite the wide use of permanent prostate implants for the treatment of early stage prostate cancer, there is no consensus for optimal pre-implant planning guidelines that results in maximal post-implant target coverage. The purpose of this study was to compare post-implant target volume coverage and dosimetry between patients treated before and after Radiation Therapy Oncology Group (RTOG) 98-05 guidelines were adopted using several dosimetric endpoints. Materials and methods: Ten consecutively treated patients before the adoption of the RTOG 98-05 planning guidelines were compared with ten consecutively treated patients after implementation of the guidelines. Pre-implant planning for patients treated pre-RTOG was based on the clinical target volume (CTV) defined by the pre-implant TRUS definition of the prostate. The CTV was expanded in each dimension according to RTOG 98-05 and defined as the planning target volume. The evaluation target volume was defined as the post-implant computed tomography definition of the prostate based on RTOG 98-05 protocol recommendations. Implant quality indicators included V100, V90, V100, and Coverage Index (CI). Results: The pre-RTOG median V100, V90, D90, and CI values were 82.8, 88.9%, 126.5 Gy, and 17.1, respectively. The median post-RTOG V100, V90, D90, and CI values were 96.0, 97.8%, 169.2 Gy, and 4.0, respectively. These differences were all statistically significant. Conclusions: Implementation of the RTOG 98-05 implant planning guidelines has increased coverage of the prostate by the prescription isodose lines compared with our previous technique, as indicated by post-implant dosimetry indices such as V100, V90, D90. The CI was also improved significantly with the protocol guidelines. Our data confirms the validity of the RTOG 98-05 implant guidelines for pre-implant planning as it relates to enlargement of the CTV to ensure adequate margin between the CTV and the prescription isodose lines.

Original languageEnglish (US)
Pages (from-to)173-179
Number of pages7
JournalRadiotherapy and Oncology
Volume66
Issue number2
DOIs
StatePublished - Feb 1 2003
Externally publishedYes

Fingerprint

Radiation Oncology
Iodine
Prostate
Radiotherapy
Guidelines
Prescriptions
Prostatic Neoplasms
Tomography

Keywords

  • Brachytherapy
  • Dosimetry
  • Iodine-125
  • Permanent prostate implant
  • Prostatic neoplasms
  • Radiation Therapy Oncology Group

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Urology

Cite this

Impact of target volume coverage with Radiation Therapy Oncology Group (RTOG) 98-05 guidelines for transrectal ultrasound guided permanent Iodine-125 prostate implants. / Horwitz, Eric M.; Mitra, Raj K.; Uzzo, Robert G.; Das, Indra J.; Pinover, Wayne H.; Hanlon, Alexandra L.; McNeeley, Shawn W.; Hanks, Gerald E.

In: Radiotherapy and Oncology, Vol. 66, No. 2, 01.02.2003, p. 173-179.

Research output: Contribution to journalArticle

Horwitz, Eric M. ; Mitra, Raj K. ; Uzzo, Robert G. ; Das, Indra J. ; Pinover, Wayne H. ; Hanlon, Alexandra L. ; McNeeley, Shawn W. ; Hanks, Gerald E. / Impact of target volume coverage with Radiation Therapy Oncology Group (RTOG) 98-05 guidelines for transrectal ultrasound guided permanent Iodine-125 prostate implants. In: Radiotherapy and Oncology. 2003 ; Vol. 66, No. 2. pp. 173-179.
@article{b1dd10273f934e6e81fef594485b6119,
title = "Impact of target volume coverage with Radiation Therapy Oncology Group (RTOG) 98-05 guidelines for transrectal ultrasound guided permanent Iodine-125 prostate implants",
abstract = "Purpose: Despite the wide use of permanent prostate implants for the treatment of early stage prostate cancer, there is no consensus for optimal pre-implant planning guidelines that results in maximal post-implant target coverage. The purpose of this study was to compare post-implant target volume coverage and dosimetry between patients treated before and after Radiation Therapy Oncology Group (RTOG) 98-05 guidelines were adopted using several dosimetric endpoints. Materials and methods: Ten consecutively treated patients before the adoption of the RTOG 98-05 planning guidelines were compared with ten consecutively treated patients after implementation of the guidelines. Pre-implant planning for patients treated pre-RTOG was based on the clinical target volume (CTV) defined by the pre-implant TRUS definition of the prostate. The CTV was expanded in each dimension according to RTOG 98-05 and defined as the planning target volume. The evaluation target volume was defined as the post-implant computed tomography definition of the prostate based on RTOG 98-05 protocol recommendations. Implant quality indicators included V100, V90, V100, and Coverage Index (CI). Results: The pre-RTOG median V100, V90, D90, and CI values were 82.8, 88.9{\%}, 126.5 Gy, and 17.1, respectively. The median post-RTOG V100, V90, D90, and CI values were 96.0, 97.8{\%}, 169.2 Gy, and 4.0, respectively. These differences were all statistically significant. Conclusions: Implementation of the RTOG 98-05 implant planning guidelines has increased coverage of the prostate by the prescription isodose lines compared with our previous technique, as indicated by post-implant dosimetry indices such as V100, V90, D90. The CI was also improved significantly with the protocol guidelines. Our data confirms the validity of the RTOG 98-05 implant guidelines for pre-implant planning as it relates to enlargement of the CTV to ensure adequate margin between the CTV and the prescription isodose lines.",
keywords = "Brachytherapy, Dosimetry, Iodine-125, Permanent prostate implant, Prostatic neoplasms, Radiation Therapy Oncology Group",
author = "Horwitz, {Eric M.} and Mitra, {Raj K.} and Uzzo, {Robert G.} and Das, {Indra J.} and Pinover, {Wayne H.} and Hanlon, {Alexandra L.} and McNeeley, {Shawn W.} and Hanks, {Gerald E.}",
year = "2003",
month = "2",
day = "1",
doi = "10.1016/S0167-8140(02)00387-0",
language = "English (US)",
volume = "66",
pages = "173--179",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Impact of target volume coverage with Radiation Therapy Oncology Group (RTOG) 98-05 guidelines for transrectal ultrasound guided permanent Iodine-125 prostate implants

AU - Horwitz, Eric M.

AU - Mitra, Raj K.

AU - Uzzo, Robert G.

AU - Das, Indra J.

AU - Pinover, Wayne H.

AU - Hanlon, Alexandra L.

AU - McNeeley, Shawn W.

AU - Hanks, Gerald E.

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Purpose: Despite the wide use of permanent prostate implants for the treatment of early stage prostate cancer, there is no consensus for optimal pre-implant planning guidelines that results in maximal post-implant target coverage. The purpose of this study was to compare post-implant target volume coverage and dosimetry between patients treated before and after Radiation Therapy Oncology Group (RTOG) 98-05 guidelines were adopted using several dosimetric endpoints. Materials and methods: Ten consecutively treated patients before the adoption of the RTOG 98-05 planning guidelines were compared with ten consecutively treated patients after implementation of the guidelines. Pre-implant planning for patients treated pre-RTOG was based on the clinical target volume (CTV) defined by the pre-implant TRUS definition of the prostate. The CTV was expanded in each dimension according to RTOG 98-05 and defined as the planning target volume. The evaluation target volume was defined as the post-implant computed tomography definition of the prostate based on RTOG 98-05 protocol recommendations. Implant quality indicators included V100, V90, V100, and Coverage Index (CI). Results: The pre-RTOG median V100, V90, D90, and CI values were 82.8, 88.9%, 126.5 Gy, and 17.1, respectively. The median post-RTOG V100, V90, D90, and CI values were 96.0, 97.8%, 169.2 Gy, and 4.0, respectively. These differences were all statistically significant. Conclusions: Implementation of the RTOG 98-05 implant planning guidelines has increased coverage of the prostate by the prescription isodose lines compared with our previous technique, as indicated by post-implant dosimetry indices such as V100, V90, D90. The CI was also improved significantly with the protocol guidelines. Our data confirms the validity of the RTOG 98-05 implant guidelines for pre-implant planning as it relates to enlargement of the CTV to ensure adequate margin between the CTV and the prescription isodose lines.

AB - Purpose: Despite the wide use of permanent prostate implants for the treatment of early stage prostate cancer, there is no consensus for optimal pre-implant planning guidelines that results in maximal post-implant target coverage. The purpose of this study was to compare post-implant target volume coverage and dosimetry between patients treated before and after Radiation Therapy Oncology Group (RTOG) 98-05 guidelines were adopted using several dosimetric endpoints. Materials and methods: Ten consecutively treated patients before the adoption of the RTOG 98-05 planning guidelines were compared with ten consecutively treated patients after implementation of the guidelines. Pre-implant planning for patients treated pre-RTOG was based on the clinical target volume (CTV) defined by the pre-implant TRUS definition of the prostate. The CTV was expanded in each dimension according to RTOG 98-05 and defined as the planning target volume. The evaluation target volume was defined as the post-implant computed tomography definition of the prostate based on RTOG 98-05 protocol recommendations. Implant quality indicators included V100, V90, V100, and Coverage Index (CI). Results: The pre-RTOG median V100, V90, D90, and CI values were 82.8, 88.9%, 126.5 Gy, and 17.1, respectively. The median post-RTOG V100, V90, D90, and CI values were 96.0, 97.8%, 169.2 Gy, and 4.0, respectively. These differences were all statistically significant. Conclusions: Implementation of the RTOG 98-05 implant planning guidelines has increased coverage of the prostate by the prescription isodose lines compared with our previous technique, as indicated by post-implant dosimetry indices such as V100, V90, D90. The CI was also improved significantly with the protocol guidelines. Our data confirms the validity of the RTOG 98-05 implant guidelines for pre-implant planning as it relates to enlargement of the CTV to ensure adequate margin between the CTV and the prescription isodose lines.

KW - Brachytherapy

KW - Dosimetry

KW - Iodine-125

KW - Permanent prostate implant

KW - Prostatic neoplasms

KW - Radiation Therapy Oncology Group

UR - http://www.scopus.com/inward/record.url?scp=0037295465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037295465&partnerID=8YFLogxK

U2 - 10.1016/S0167-8140(02)00387-0

DO - 10.1016/S0167-8140(02)00387-0

M3 - Article

C2 - 12648789

AN - SCOPUS:0037295465

VL - 66

SP - 173

EP - 179

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 2

ER -